Companies that continue to treat market entry as a formulaic process will soon find themselves retreating at a loss.

A Morgan Stanley analyst identifies the point where investors might find an attractive entry point to get back in the market.

For speciality biopharma companies based outside of Europe, the prospect of commercialising here can be daunting – but there are smart solutions to cracking this lucrative market. There is a ...